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Chemokines are small molecular weight proteins primarily known to drive migration of
immune cell populations. In both acute and chronic liver injury, hepatic chemokine expres-
sion is induced resulting in inflammatory cell infiltration, angiogenesis, and cell activation
and survival. During acute injury, massive parenchymal cell death due to apoptosis and/or
necrosis leads to chemokine production by hepatocytes, cholangiocytes, Kupffer cells,
hepatic stellate cells, and sinusoidal endothelial cells. The specific chemokine profile
expressed during injury is dependent on both the type and course of injury. Hepatotox-
icity by acetaminophen for example leads to cellular necrosis and activation of Toll-like
receptors while the inciting insult in ischemia reperfusion injury produces reactive oxy-
gen species and subsequent production of pro-inflammatory chemokines. Chemokine
expression by these cells generates a chemoattractant gradient promoting infiltration by
monocytes/macrophages, NK cells, NKT cells, neutrophils, B cells, andT cells whose activ-
ity are highly regulated by the specific chemokine profiles within the liver. Additionally,
resident hepatic cells express chemokine receptors both in the normal and injured liver.
While the role of these receptors in normal liver has not been well described, during injury,
receptor up-regulation, and chemokine engagement leads to cellular survival, prolifera-
tion, apoptosis, fibrogenesis, and expression of additional chemokines and growth factors.
Hepatic-derived chemokines can therefore function in both paracrine and autocrine fash-
ions further expanding their role in liver disease. More recently it has been appreciated
that chemokines can have diverging effects depending on their temporal expression pat-
tern and the type of injury. A better understanding of chemokine/chemokine receptor axes
will therefore pave the way for development of novel targeted therapies for the treatment
of liver disease.
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INTRODUCTION
Chemokines are small molecular weight proteins (8–13 kDa) ini-
tially identified by their ability to provide migratory cues to
inflammatory cells (Wasmuth et al., 2010). Their expression is
up-regulated in nearly all forms of injury in all tissues, leading
to infiltration by immune cells. To date, more than 50 differ-
ent chemokines and 20 chemokine receptors have been identified
(Bromley et al., 2008). Most chemokine receptors engage more
than one ligand leading to redundancy in chemokine signaling and
divergent outcomes following signaling through a single receptor
(Bromley et al., 2008).
Chemokines are subdivided into two broad categories based
on their amino acid sequences. CC chemokines contain two
adjacent N-terminus cysteine residues while the N-terminal cys-
teines in CXC chemokines are separated by a single amino
acid. These cysteine residues form disulfide bonds with addi-
tional internal cysteines providing tertiary structure to the
protein. Two additional categories, C- and CX3C-chemokines
have either a single N-terminus cysteine or two cysteine
residues separated by three amino acids, respectively. Addition-
ally, CXC chemokines can be further subdivided based on spe-
cific sequence motifs (ELR positive/negative) that impart spe-
cific functional properties to the chemokine (Bajetto et al., 2002;
Fernandez and Lolis, 2002; Oo et al., 2010; Wasmuth et al.,
2010).
The field of chemokine biology has rapidly progressed and
additional functions are recognized well beyond immune cell
migration. Chemokine receptors have been identified on non-
immune cells, and as a result, their roles have expanded to include
organ homeostasis and non-inflammatory aspects of injury (Rossi
et al., 1999; Shibuta et al., 2002; Zlotnik et al., 2011). The func-
tions of chemokines have therefore expanded to include: cellular
differentiation, survival, proliferation, and apoptosis in addition
to the ability to modulate development, organ fibrogenesis, vascu-
lar angiogenesis, and tumor metastasis (Shibuta et al., 2002; Hong
et al., 2009; Zlotnik et al., 2011; Mukaida and Baba, 2012).
For the purposes of this review we discuss chemokine responses
in both immune cells and liver parenchymal cells. Although infil-
trating immune cells secrete chemokines, the primary sources in
the liver are hepatocytes, Kupffer cells, stellate cells, sinusoidal
endothelial cells, and biliary epithelial cells. Together, these cells
secrete an array of chemokines that drive immune cell infiltration,
development of chronic inflammation, liver injury and regenera-
tion, and progression and resolution of fibrosis (Karlmark et al.,
2008; Oo et al., 2010; Wasmuth et al., 2010). The numerous
and often disparate functions of chemokines in the liver reflect
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the divergent temporal expression of these molecules and their
receptors by immune and resident hepatic cells.
The regulation of both chemokine and receptor expression is
modulated by a range of stimuli including growth factors (Ger-
ritsma et al., 1998), cytokines (Harvey et al., 2003), cellular stres-
sors (bile acids, ROS, etc.; Friedman, 2008a,b; Steib et al., 2010),
cellular activation by apoptotic bodies (Zernecke et al., 2009), and
release of cellular debris from necrotic cells (Jaeschke et al., 2002).
Chemokines function as paracrine signals and in autocrine loops,
with both positive and negative feedback elements. The complexity
of these networks is immense and therefore we highlight herein
those aspects that are most instructive in clarifying chemokine
biology in acute liver injury (ALI; Table 1).
CCL2 PROMOTES MONOCYTE/MACROPHAGE RECRUITMENT
AND CYTOKINE PRODUCTION DURING ACUTE LIVER INJURY
CCL2 (MCP-1) is among the most extensively studied chemokines
in liver injury. Its primary role is the recruitment of monocytes and
macrophages via its receptor, CCR2, but NK cells and lymphocytes
also express CCR2 and migrate in response to CCL2 (Hokeness
et al., 2005; Karlmark et al., 2008). Intrahepatic and serum levels
of CCL2 are increased in patients with fulminant hepatic failure
and also in murine models of acute liver failure (Possamai et al.,
2010). Injured hepatocytes and activated Kupffer cells are thought
to be the primary sources of hepatic CCL2, however, hepatic stel-
late cells and liver sinusoidal endothelial cells can also secrete this
molecule (Leifeld et al., 2003; Friedman, 2008b; Kolios et al., 2008;
Chen et al., 2010; Figure 1).
The role of CCL2 in liver injury is twofold. First, as CCL2
levels in the serum rise, it stimulates monocytic hematopoiesis
and increased differentiation and production of the mono-
cyte/macrophage lineages (Leifeld et al., 2003; Friedman, 2008b;
Kolios et al., 2008; Chen et al., 2010). Furthermore, CCL2 levels
in the liver are greater than in the blood, establishing a gradi-
ent driving macrophage egress from the bone marrow (Dambach
et al., 2002; Tsou et al., 2007; Karlmark et al., 2009). Moreover,
it has been shown that it predominantly recruits the inflam-
matory Gr1 high monocyte-derived macrophage subpopulation
(Karlmark et al., 2009). Macrophages have distinctive roles in
initiation, propagation, and resolution of ALI. Their involve-
ment is critical during the initial inflammatory stages by phago-
cytosing necrotic cells, secreting cytokines and growth factors,
and recruiting inflammatory cells (Duffield, 2003). Additionally,
macrophages assist in the reparative phase leading to hepatic
remodeling and the return to normal liver function (Duffield et al.,
2005).
Macrophage derived chemokines, cytokines, and growth factors
can influence hepatocyte function and recruitment of additional
immune cell populations. TNF-α which leads to hepatocyte cell
death, is increased early in acetaminophen (APAP) injury and is
secreted predominantly by macrophages but also hepatocytes and
other immune cells (Hassan et al., 2007). Additionally, IFN-γ, a
pro-inflammatory cytokine released by macrophages as well as
CCR2-dependent T cells and NKT cells, may promote injury by
stimulating hepatic inflammation and amplifying liver damage
(Hogaboam et al., 2000; Dambach et al., 2002). Loss of IFN-γ sig-
naling in both KO mice or mice treated with IFN-γ neutralizing Ta
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FIGURE 1 | CCL2 monocyte/macrophage recruitment. In response to
injury, hepatocytes and Kupffer cells secrete CCL2 leading to liver infiltration
by monocytes and macrophages from the periphery. Additionally, CCL2
promotes monocytic hematopoiesis in the bone marrow increasing the pool
of circulating monocytes/macrophages. In the liver, macrophages secrete
TNF-α and IFN-γ promoting inflammation and hepatocyte cell death while also
removing necrotic cells which is important for liver remodeling and return to
normal function.
antibodies demonstrates a protective effect in APAP or ConA
induced ALI (Jaruga et al., 2004; Dong et al., 2005). Interest-
ingly, IFN-γ is important in regulation of the CXCL9–11/CXCR3
chemokine axis, which is reviewed below.
Given the dependence of macrophage recruitment on
the CCL2/CCR2 axis, many groups have utilized mono-
cyte/macrophage depletion studies to establish the relevance of
the CCL2/CCR2 axis. While the overall role of CCL2 recruited
macrophages in ALI appears to be protective, conflicting reports
have made it difficult to clearly define the role of CCL2 dur-
ing injury (Laskin et al., 1995; Michael et al., 1999; Hogaboam
et al., 2000; Dambach et al., 2002; Ju et al., 2002; Holt et al.,
2008; Karlmark et al., 2009). The method of macrophage deple-
tion (clodronate, gadolinium chloride, CD11b DTR), the type of
injury (APAP, CCl4, Ischemia reperfusion), and the extent of injury
all influence the interpretation of how macrophages affect liver
function.
One technical concern is that many macrophage depletion
methods affect other cell lineages including dendritic cells and
bone marrow hematopoietic cells. Additionally, as a result of
strain differences and the dependence of bone marrow stem cells
egress on CCL2/CCR2, global knockouts of this axis have failed to
delineate the specific role of hepatic-derived CCL2 during injury.
Overall, it appears that loss of CCL2 function perturbs mono-
cyte/macrophage infiltration into the injured liver with a con-
comitant dampening of pro-inflammatory cytokine production.
Therefore, future studies will need to utilize conditional CCL2
or CCR2 knockouts from specific hepatic and immune cell pop-
ulations in order to determine the cellular populations involved
in ALI.
Macrophages recruited by CCL2 are involved in both the initial
stages of injury during ALI and the reparative stages. However,
little data exists on the role of macrophages during liver regenera-
tion or during restoration after acute injury. In murine models
of chronic liver injury and fibrosis, there exist two waves of
macrophage infiltration responsible for both disease progression
and regression (although this is not CCL2-dependent; Duffield
et al., 2005). Similar studies have not been undertaken in ALI
models, which might shed additional light on the role of CCL2
and infiltrating macrophages in ALI.
The concept of multiple waves of macrophage has also been
shown in patients with ALI. After APAP-induced acute liver failure
there is an increase in hepatic CCL2 which directly correlated with
clinical outcomes. Furthermore, there is a specific and marked
reduction in circulating monocytes which negatively correlated
with the hepatic CCL2 levels indicating that their recruitment into
the inflamed liver is via CCR2. In areas of liver necrosis there was
a predominance proliferating resident Kupffer cells. This study
indicates that the appearance of macrophages early after injury
are derived from circulating monocytes and resident proliferating
Kupffer cells represent a second wave implicated in organ resolu-
tion (Antoniades et al., 2012). While not definitive, these results
impressively mimic rodent models of macrophage recruitment in
rodent models.
While the majority of studies of CCL2 have focused on its effect
on monocytes and macrophages, it can also recruit/activate T cell
and NKT cell populations, albeit to a lesser extent. Neutraliza-
tion of the CCL2/CCR2 axis in the T cell-mediated ConA injury
model leads to an increase in hepatic injury, indicating that, in this
model, CCL2 may be anti-inflammatory (Ajuebor et al., 2003).
Mice treated with CCR2 neutralizing serum showed a decrease
in TNF-α and IFN-γ, but worse hepatitis and an unexpected and
significant increase in IL-4, representing a shift from a Th1 to a
Th2 response. ConA treatment increased CCR2 expression on res-
ident hepatic NKT cells and receptor engagement dampened their
secretion of IL-4. Therefore, blocking this axis actually increased
the expression of IL-4, indicating that CCL2 may also function in
an anti-inflammatory manner.
The only resident liver cells to express CCR2 are Kupffer cells
and hepatic stellate cells (Friedman, 2008b; Krohn et al., 2009). As
noted previously, Kupffer cells are an important source of CCL2
whose production is stimulated by ROS. The specific role of resi-
dent hepatic cell CCR2 in ALI has not been demonstrated, but in
models of chronic liver injury, the stellate cell’s response to CCL2
is important in the production of ROS, cellular chemotaxis, and
the acquisition of a pro-fibrogenic phenotype. Given the limited
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data regarding the role of hepatic stellate cells during ALI, addi-
tional work is required to determine the role of CCL2 on resident
hepatic cell function during acute injury.
CXCL9–11 RECRUITS T CELL POPULATIONS INVOLVED IN
IMMUNE MODULATION
The CXCL9–11/CXCR3 axis is unique based on the alternative reg-
ulation of its three ligands, which are all induced by IFN-γ. CXCR3
is primarily expressed on CD4+ Th1 helper cells, CD8+ cyto-
toxic lymphocytes, and innate lymphocytes including NK cells,
NKT cells, and dendritic cell subsets. During activation by profes-
sional antigen presenting cells, CXCR3 is rapidly up-regulated on
leukocyte populations (Groom and Luster, 2011; Figure 2).
Similar to other chemokine axes,CXCL9–11 signaling is charac-
terized by significant redundancy, however each of the chemokines
has a distinctive role. Expression of all three ligands is mediated by
IFN-γ, but the identification of unique promoter elements for each
ligand leads to a distinct spatial and temporal expression pattern.
Briefly, CXCL9 is dependent solely on IFN-γ whereas CXCL11 can
also be induced by IFN-β and CXCL10 by both IFN-α/IFN-β and
NF-κB activation. Hepatocytes, stellate cells, sinusoidal endothe-
lial cells, and activated infiltrating lymphocytes all secrete CXCR3
ligands in response to these stimuli. Differences in the sensitivity
of each cell type to IFN-γ signaling along with the differences in
the ligand promoters leads to the differential expression patterns
seen in liver disease (Luster et al., 1985; Farber, 1990;Ohmori and
Hamilton, 1993, 1997;Ohmori et al., 1993, 1997; Cole et al., 1998;
Majumder et al., 1998; Tensen et al., 1999; Medoff et al., 2006; Yang
et al., 2007).
In patients with chronic liver disease, hepatic levels of both
CXCR3 and its ligands are increased, and CXCR3 ligand levels
correlate with the severity of disease (Apolinario et al., 2002). Addi-
tionally, in mouse models of chronic disease, CXCR3 is protective
through several mechanisms. While no human data exists on the
role of CXCR3 in ALI, CXCR3-deficient mice point to its being
hepatoprotective (Hokeness et al., 2007; Zaldivar et al., 2012). Th1-
polarized T cells, which provide a protective immune response, are
rapidly recruited to the liver after injury in a CXCR3-dependent
manner. Additionally, a large subset of Foxp3+/CD25+ regula-
tory T cells (Tregs) found in the liver during injury are CXCR3+,
and this population is diminished in CXCR3-deficient mice. Loss
of CXCR3 therefore affects recruitment of both effector T cell
populations and T regulatory cells (Erhardt et al., 2011). The bal-
ance between these populations influences the outcome following
blockade of this axis and may explain the contrasting results seen
in different experimental models.
Ischemia reperfusion (I/R) injury is a major concern following
liver transplantation and is an important contributor to liver rejec-
tion in this setting. After I/R, levels of CXCL9–11 are increased
early after injury leading to infiltration of CXCR3+ T cells.
Blocking this interaction in rats decreases hepatocellular damage
and increases survival. Similarly, studies of cardiac and islet cell
allografts indicate that blocking CXCL10 and CXCL11 prolongs
survival and prevents acute allograft rejection by inhibiting the
recruitment of effector T cells (Horiguchi et al., 2002).
Tregs have important functions in controlling immune cell acti-
vation within the liver. Patients with autoimmune hepatitis, as well
as autoimmune liver disease, have decreased numbers of Tregs. In
the T cell-mediated ConA injury model, CXCL9–11 expression is
increased and mice deficient for CXCR3 are significantly more sus-
ceptible to ConA injury. Similar to other models, the total number
of CXCR3+ T cells was decreased as were the number of hepatic
Tregs. However, in this model, the decrease in infiltrating CXCR3+
effector T cells does not compensate for the loss of hepatic Tregs,
and nonetheless leads to increased injury and lethality. Consistent
with this finding, the number of Tregs in the spleen and lymph
nodes were increased, indicating that they failed to recruit to the
liver in the absence of CXCR3 (Erhardt et al., 2011). Similarly, loss
FIGURE 2 | CXCL9–11T cell recruitment: CXCL9–11 expression is
increased in an IFN-γ dependent manner. Numerous T cell populations,
including Th1-polarized T cells, Tregs, and effector T cells are recruited to the
liver in a CXCR3-dependent manner. The specific type of injury will determine
the relative recruitment of Tregs vs. effector T cells and the
protective/injurious role of the CXCL9–11/CXCR3 axis.
Frontiers in Physiology | Gastrointestinal Sciences June 2012 | Volume 3 | Article 213 | 4
Saiman and Friedman Role of chemokines in acute liver injury
of IFN-γ (and subsequently CXCL9–11 up-regulation) or neutral-
ization of CXCL10 leads to decreased hepatic Tregs and enhanced
hepatic inflammation. This effect is partially mediated by resident
liver NKT cells, which express high levels of IFN-γ in response
to injury. Mice deficient in NKT cells therefore show a marked
decrease in Treg recruitment, as do mice deficient for IFN-γ.
These results point to the difficulty of establishing whether
a single chemokine is protective or injurious. Undoubtedly, the
specific disease process and chemokine/cytokine signature will
determine the relative contribution of each cell type, and whether
inhibition of the axis will be protective or injurious, further
highlighting the multidimensional approach required to under-
standing the function of any chemokine axis (Ajuebor et al.,
2007).
In models of ALI, CXLC10, and CXCR3 are up-regulated upon
APAP administration, whereas recombinant CXCL10 is hepato-
protective. The effect of CXCL10 is indirect by increasing hepa-
tocyte expression of CXCR2, which is protective in certain injury
models, and blocking CXCR2 abrogates the effect of exogenously
administered CXCL10. These results are particularly interesting,
as hepatocytes do not express CXCR3, and therefore the up-
regulation of CXCR2 on hepatocytes must be regulated by an
independent yet unidentified signaling axis (Bone-Larson et al.,
2001).
Within the liver CXCR3 is expressed by hepatic stellate cells and
liver sinusoidal endothelial cells, and is anti-fibrotic in chronic
injury (Shields et al., 1999; Crosby et al., 2009; Wasmuth et al.,
2009). CXCR3 ligands have seemingly opposing effects on hepatic
stellate cells. CXCL9 decreases collagen mRNA expression leading
to a less activated phenotype, while CXCL10 promotes hepatic stel-
late cell migration (Wasmuth et al., 2009). Such opposing effects
may reflect different roles stellate cells play during liver injury
or could categorize subpopulations of these cells with divergent
functions. Furthermore, CXCL9–11 ligands are angiostatic, and
administration of CXCL9 in vivo inhibits neoangiogenisis and
prevents development of fibrosis (Sahin et al., 2012).
As a final note, it is important to recognize that there are mouse
strain differences in CXCL9–11 expression. C57Bl/6 mice do not
express CXCL11 due to a point mutation leading to an early stop
codon. Bl/6 mice are still responsive to exogenous CXCL11, but
because CXCL9 and CXLC10 knockout mice were backcrossed
onto a Bl/6 background it is difficult to distinguish between the
function of each ligand (Sahin et al., 2012).
CXCR1/CXCR2 LIGANDS PROMOTE NEUTROPHIL MIGRATION
TO THE LIVER AND REGULATE HEPATOCYTE SURVIVAL AND
PROLIFERATION
The CXCL1, CXCL2, and CXCL8 chemokine axis is especially
important in acute injury given the dependence of neutrophil and
macrophage chemotaxis on CXCR1/CXCR2 ligands (Chen et al.,
2006; Ishida et al., 2006; Kobayashi, 2008). Several ligands sig-
nal through CXCR1/CXCR2, including CXCL8 (IL-8), found only
in humans, and CXCL1 and CXCL2 (KC and MIP-2) present in
both humans and mice. In patients, CXCL8 levels are increased
in alcoholic hepatitis, as well as in APAP overdose, which are
predictive of hepatocellular damage (James et al., 2001; Zim-
mermann et al., 2011). Additionally, post-liver transplantation,
patients with elevated serum CXCL8 have higher serum transam-
inases (Ilmakunnas et al., 2010). In view of the direct correlation
between CXCL8 levels and hepatic function after acute injury,
much research has focused on the role of CXCR1/CXCR2 in I/R
and APAP injury models. Furthermore, this axis is of great interest
due to the expression of CXCR1/CXCR2 by hepatocytes, enabling
these chemokines to directly affect both acute inflammation and
hepatocyte survival/function (Figure 3).
During injury most hepatic cells express CXCR1/CXCR2 lig-
ands including hepatocytes, Kupffer cells, stellate cells, endothelial
cells, and biliary epithelial cells (Kuboki et al., 2008). After I/R
injury, Kupffer cell activation leads to a release of ROS and sub-
sequent activation of hepatocyte-derived chemokines CXCL1 and
CXCL2 (Jaeschke et al., 1991; Jaeschke and Farhood, 2002; Kuboki
et al., 2008). Hepatocyte injury due to exposure to ethanol, IL-1,
and TNF-α has also been shown to result in CXCL8 expression by
human hepatocytes (Stefanovic and Stefanovic, 2006).
Neutrophils express CXCR1 and CXCR2, and increased ligand
expression after injury is associated with neutrophil infiltration
(Kobayashi, 2008). CXCL8 binds with high affinity to CXCR1
and with lower affinity to CXCR2, which binds an additional six
chemokines. Both receptors drive neutrophil chemotaxis, but a
neutrophil respiratory burst occurs only through CXCR1, indicat-
ing distinct roles for each receptor. A feature of all chemokines,
which has been extensively studied in CXCL8, is that they can exist
as a monomer, dimer, or a mixture of the two under physiologi-
cal conditions. These two forms of CXCL8 differentially regulate
CXCR1 phosphorylation, desensitization, and receptor internal-
ization, but not that of CXCR2. In general, monomeric CXCL8
shows increased activity via CXCR1, and that in models of lung
injury the ability of CXCL8 to reversibly exist as both a monomer
and dimer regulates neutrophil chemotaxis and function (Nasser
et al., 2009).
The development of effective chemokine gradients is depen-
dent on the interactions between tissue-expressed glycosamino-
glycans (GAGs) and chemokines. Monomeric and dimeric
chemokine forms have different binding affinities for GAGs,
and changes in the monomer/dimer equilibrium will affect the
chemokine gradients established within an organ. Chemokine
dimerization therefore adds an additional level of regulation to
chemokine axes (Gangavarapu et al., 2012).
In models of I/R, receptor inhibition by neutralizing antibodies
leads to decreased neutrophil infiltration and less damage over-
all. Similarly, CXCR2 deficient mice exhibit decreased neutrophil
accumulation at 24 h, but not at 96 h, indicating that CXCR2
might be important specifically in early neutrophil infiltration.
Knockout mice also exhibit less injury (ALT/AST) and hepatic
necrosis (Kuboki et al., 2008). While there is a decrease in neu-
trophil infiltration, expression levels of CXCR2 chemokines are
increased, indicating a potential negative feedback loop through
CXCR2. Similarly, in models of APAP-induced injury, loss of
CXCR2 leads to decreased neutrophil and macrophage infiltration
and less injury (Hogaboam et al., 1999a; Hu and Colletti, 2010).
However, when only neutrophils are depleted using a neutrophil
specific depleting antibody, the protective effect is even greater. The
authors contend that production of iNOS by neutrophils leads to
increased injury, but that macrophage derived heme-oxygenase
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FIGURE 3 | CXCL1/CXCL2/CXCL8 neutrophil recruitment and hepatocyte
proliferation. Neutrophils are recruited from the periphery via CXCR2 in
response to increased hepatic levels of CXCL1, CXCL2, and CXCL8 (in
humans). Hepatic injury also promotes expression of CXCR1 and increased
expression of CXCR2 on hepatocytes. Receptor engagement leads to changes
in hepatocyte survival and proliferation in a dose dependent mechanism.
(HO)-1 is protective. CXCR2 KO mice exhibit increased injury
compared with the neutrophil depleted mice due to the additional
loss of macrophage derived HO-1 (Ishida et al., 2006).
Among the most interesting aspects of this axis is
CXCR1/CXCR2 expression by hepatocytes and their role in sur-
vival and proliferation. While CXCR2 is expressed under normal
physiological conditions and is up-regulated with injury, hepa-
tocyte expression of CXCR1 is detected only after injury. After
I/R injury, signaling through CXCR2 is detrimental to hepatocyte
proliferation and regeneration. Loss of CXCR2 function leads to
an increase in STAT3 and NK-κB signaling which regulates liver
regeneration. Furthermore, CXCR1 expression is increased during
I/R injury, and while inhibition of CXCR1 does not mitigate early
liver injury and neutrophil infiltration, it appears to be involved
in the reparative and regenerative phase after I/R injury (Kuboki
et al., 2008; Clarke et al., 2011).
Alternatively, in models of APAP injury and partial hepatec-
tomy, CXCR2 activation by recombinant CXCL2 is mitogenic and
promotes liver regeneration, while loss of CXCR2 leads to marked
liver necrosis and hemorrhaging (Sakai et al., 2011). Currently,
the only available treatment for APAP toxicity includes admin-
istration of N -acetylcysteine, however, the window of efficacy is
only within 8 h after APAP ingestion. Conversely, administration
of CXCL2 is only effective if administered 10 h after the initial
injury, indicating that its role is to support hepatocyte survival
and proliferation after the initial injury (Hu and Colletti, 2010).
In another model, adenoviral administration of CXCL2 inhibits
neutrophil influx while promoting hepatocyte proliferation after
APAP, while CXCL2 inhibition increased liver injury and overall
mortality (Hogaboam et al., 1999b).
One explanation for the discrepancies in assessing the effects
of this axis on hepatocyte proliferation is that high doses of
CXCR2 ligands are hepatotoxic while low doses are hepatopro-
tective. In vitro studies indicate that hepatocyte treatment with
equal concentration of CXCR2 ligands, CXCL1 and CXCL2, may
act synergistically and adjusting the relative concentration of each
chemokine alters the overall effect (Kuboki et al., 2008). As numer-
ous chemokines signal through CXCR2, differences in injury
models may induce unique expression levels of CXCR2 binding
chemokines leading to divergent outcomes.
CXCL12 PROMOTES HEMATOPOIETIC STEM CELL
RECRUITMENT TO THE LIVER AND NEUTROPHIL EGRESS
FROM THE BONE MARROW
CXCL12 (SDF-1α), which binds to the CXCR4 receptor, regu-
lates organ homeostasis and several pathological responses (Naga-
sawa et al., 1996). CXCL12 is crucial in early embryogenesis,
hematopoiesis, and angiogenesis, as well as maintenance of the
bone marrow stem cell niche. A unique feature of CXCL12 is
its high expression levels even in normal tissues that is further
up-regulated with injury. In the uninjured liver, biliary epithelial
cells constitutively express CXCL12 and in patients with chronic
injury and fibrosis, CXCL12 levels increase in parallel with the
extent of fibrotic injury (Wald et al., 2004). In distinction to many
other chemokines in the liver, CXCL12 is not expressed by hepa-
tocytes and Kupffer cells, but is localized to biliary epithelial cells,
cells of the ductular reaction, hepatic stellate cells, and sinusoidal
endothelial cells (Sawitza et al., 2009). Dissecting the specific role
of the CXCL12/CXCR4 axis has proven difficult given the lack
of a suitable animal model. As mentioned, CXCL12 is crucial for
embryogenesis and mice deficient in either CXCL12 or its receptor
CXCR4 are not viable due to a lack of cardiac development and a
failure of hematopoiesis (Nagasawa et al., 1996; Figure 4).
Most inflammatory cells, including neutrophils, monocytes,
and B and T lymphocytes express CXCR4 and locally produced
CXCL12 recruits immune cells to the injured site and promotes
angiogenesis (Liekens et al., 2010). Neutrophil regulation and
egress from the bone marrow is predominantly CXCR4-dependent
and in chronic liver injury over 50% of liver infiltrating cells are
CXCR4 positive. Neutrophils contain large cytoplasmic stores of
CXCR4, which can be rapidly expressed on the cell surface in
response to cytokines, growth factors, or injurious stimuli (Link,
2005; Christopher and Link, 2007; Ramaiah and Jaeschke, 2007).
During injury, bone marrow G-CSF levels increase leading to
changes in the bone marrow CXCL12/CXCR4 axis and subse-
quent release of neutrophils (Lei et al., 2010). No study has directly
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FIGURE 4 | CXCL12 stem cell mobilization and neutrophil egress.
Increased expression of CXCL12 by stellate cells, endothelial cells, and
biliary epithelial cells promotes migration of bone marrow stem cells to
the liver. Additionally, neutrophil egress from the bone marrow is
regulated by CXCL12 and increased levels of hepatic and serum levels
promotes neutrophil egress. While not depicted, nearly 50% of liver
infiltrating cells are CXCR4 positive and localized around CXCL12-rich
periportal regions.
examined the effect of CXCR4-dependent neutrophil migration
to the liver during acute injury, but based on studies of CXCR2-
dependent neutrophil migration, the inhibition of CXCR4 driven
neutrophil migration would be protective (Cao et al., 2000). Alter-
natively, inhibition of this axis alone may lead to an unfavorable
outcome due to increased neutrophil egress from the bone marrow
that migrate to the liver.
CXCL12 also plays a role in lymphocyte adhesion, migra-
tion, and extravasation into the liver parenchyma. Treatment of
lymphocytes with CXCL12 increases ICAM-1 dependent tether-
ing and can enhance tethering and firm adhesion required for
transendothelial migration, suggesting a role for endothelial cell-
derived CXCL12 (Campbell et al., 1998; Peled et al., 1999; Goddard
et al., 2001). Additionally, liver sinusoidal endothelial cells can
present abluminal CXCL12 on their luminal cell surface via tran-
scytosis, which leads to T cell adhesion and migration across
endothelial cell membranes (Schrage et al., 2008).
The role of bone marrow derived cells in ALI has been of great
interest, with considerable progress made. It is unclear if bone
marrow cells can directly replenish hepatocytes, however, injec-
tion of autologous bone marrow cells, or increased mobilization
of bone marrow cells, are protective after ALI (Li et al., 2010;
Possamai et al., 2010; Shi et al., 2010; Inagaki and Higashiyama,
2012; Takami et al., 2012; Zhao et al., 2012). In both animal mod-
els and clinical studies, delivery of bone marrow cells or agents
that increase circulating bone marrow cells are advantageous.
Whole bone marrow and different subpopulations of cells includ-
ing CD34+, CD133+, mononuclear cells, mesenchymal stem cells,
and endothelial stem cells are all reportedly beneficial. The specific
bone marrow-derived cell type that is responsible for protection is
controversial, but the CXCL12/CXCR4 axis is implicated in many
of these models (Shafritz et al., 2006; Khurana and Mukhopadhyay,
2007; Oertel and Shafritz, 2008;Jin et al., 2009, 2010; Karlmark
et al., 2009; Baldo et al., 2010).
Myeloid cells alone are sufficient to generate hepatocytes, but
this only occurs in models of severe hepatic disease. In more mild
models including chronic CCl4 and bile duct ligation, these cells
do not directly contribute to hepatocytes, but may be beneficial
by secreting chemokines, cytokines, and growth factors thereby
establishing a specific reparative niche (Kisseleva et al., 2010).
Rats administered a sublethal dose of acute CCl4 along with
G-CSF and AMD3100, have increased survival and accumulation
of CD34+ cells around CXCL12-rich periportal areas (Mark et al.,
2010). G-CSF releases bone marrow progenitor cells by decreasing
expression of CXCL12 by bone marrow endothelium, and by acti-
vating osteoclasts, inducing their expression of proteolytic activity
which cleaves cell surface CXCR4, further releasing hematopoi-
etic stem cells into the periphery (Damon, 2009). Furthermore,
in NOD/SCID mice injected with human CD34+ stem cells, liver
engraftment is dependent on the CXCL12/CXCR4 axis. Neutral-
ization of CXCR4 with a specific antibody inhibits engraftment,
while hepatic administration of recombinant CXCL12 leads to
increased engraftment. The location of the CD34+ cells around
the CXCL12-rich periportal areas further demonstrates their
dependence on CXCL12. Finally, induction of either acute or
chronic liver injury with CCl4 increases CXCR4 expression on
human CD34+ cells and a greater degree of hepatic engraftment
(Kollet et al., 2003).
CXCL12 can also bind the CXCR7 chemokine receptor. CXCR7,
which also binds CXCL11, is classically thought to be a scaveng-
ing receptor capable of binding ligand, but unable to generate
downstream signals, effectively sequestering the chemokine and
preventing it from signaling through CXCR4 (Maksym et al., 2009;
Luker et al., 2012; Sartina et al., 2012). Other receptors including
DARC and D6 have similar scavenging properties, and their role
in liver disease is apparent from mouse models deficient in the D6
receptor. D6 knockout mice exhibit prolonged liver damage after
CCl4 injury associated with increased hepatic levels of chemokines
CCL2, CCL3, and CCL5 (Berres et al., 2009). Increased inflamma-
tory chemokines resulted in greater inflammation highlighting the
role of chemokine sequestration in the control of inflammation.
As discussed above, inflammatory cell recruitment by CXCR4
and other chemokine receptors is largely regulated by chemokine
ligand expression. However, chemokine receptor expression on
infiltrating cells is also tightly controlled and finely tunable. Cell
surface expression of CXCR4 in particular is highly regulated
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by factors including TGF-β, TNF-α, bacterial glycoproteins, and
hypoxia.
Receptor expression can be controlled through transcriptional
regulation and receptor internalization. TNF-α, IFN-γ, and LPS
specifically reduces cell surface CXCR4 expression on neutrophils,
but not lymphocytes, via receptor internalization in a time and
dose dependent manner (Nagase et al., 2002; Kim et al., 2007).
Paradoxically, however, CXCR4 mRNA levels are actually increased
after stimulation, indicating that the change in cell surface CXCR4
expression is due to receptor internalization (Kim et al., 2007).
TGF-β is implicated in all forms of liver injury and has
many functions in controlling immune cell differentiation
and chemokine receptor expression. In both neutrophils and
macrophages, TGF-β1 increases mRNA levels and cell surface
expression of CXCR4 and enhances the effect of CXCL12 stim-
ulation (Nagase et al., 2002; Chen et al., 2005). Furthermore,
treatment of both immature and mature dendritic cells with TGF-
β decreases the expression of CCR7 and increases expression of
CCR1, CCR3, CCR5, and CXCR4 leading to a chemokine receptor
profile that preferentially migrates toward sites of inflammation
(Sato et al., 2000).
The liver with its dual arterial and venous blood supply has
a low oxygen tension, which is worsened during injury, leading
to a hypoxic environment. Monocytes and macrophages increase
mRNA and cell surface expression of CXCR4 in response to
hypoxic conditions in a HIF-1α-dependent mechanism, whereas
transcript levels of CCR5 are unaffected (Schioppa et al., 2003).
CXCL12 production by endothelial cells is induced by hypoxia, fur-
ther increasing the effect of CXCL12/CXCR4 axis during hypoxia
(Hitchon et al., 2002; Santiago et al., 2011).
ADDITIONAL CHEMOKINES IN ACUTE LIVER INJURY
Two additional chemokines whose expression is induced during
ALI are CCL5 (RANTES) and CX3CL1 (Fractalkine). CCL5 which
binds to both CCR1 and CCR5 is of particular interest given the
availability of maraviroc, a CCR5 small molecule inhibitor (Proud-
foot et al., 2010). NK and NKT cells, CD4+ T cells, macrophages,
and hepatic stellate cells all express CCR5 and in models of ConA
induced hepatitis CCR5 deficiency promotes liver failure by pre-
venting NKT cell activation-induced apoptosis (Ajuebor et al.,
2006). Mice deficient for CCR5 show an unexpected increase in
CCL5 ligand, perhaps due to loss of a negative feedback through
CCR5, and an increase in CCR1-dependent NK cell recruitment
and worse injury (Ajuebor et al., 2007). Within the liver CCR5
is expressed by stellate cells and is important in promoting their
migration during chronic injury (Schwabe et al., 2003; Seki et al.,
2009). The role of CCR5 on stellate cells has not been elucidated
in models of acute injury.
CX3CL1, the only member of theCX3C family, is unique in that
it is synthesized as a transmembrane protein and can be released
by metalloproteinease cleavage. CX3CR1 is increased in patients
with either chronic or acute liver disease specifically in areas of
inflammation and in regenerating bile duct epithelia (Efsen et al.,
2002). Similar to CCR5, loss of CX3CR1 leads to greater injury and
delayed recovery after acute and chronic CCl4. Loss of CX3CR1
on macrophages promotes increased apoptosis and a more pro-
inflammatory phenotype (Aoyama et al., 2010). As different waves
of macrophages are important in injury and resolution of ALI,
similar to CCL2, CX3CL1 may be important in the different stages
of macrophage recruitment to the liver.
THERAPEUTIC POTENTIAL OF CHEMOKINE RECEPTOR
INHIBITION
The development of small molecule chemokine inhibitors and
neutralizing antibodies provides promise for modulating immune
cell infiltration during inflammatory diseases. A number of trials
have examined the use of small molecule inhibitors in autoim-
mune and infectious diseases (Proudfoot et al., 2010); however,
to date no clinical trial has examined the use of small molecule
inhibitors directly in liver disease. Despite the large amount of
data generated from knockout mice, inhibition of these axes in
human disease states has not recapitulated pre-clinical data. Block-
ing CCR2 or inhibiting CCL2 in patients with rheumatoid arthritis
(RA) did not achieve clinical endpoints (Haringman et al., 2006;
Vergunst et al., 2008). Similarly, trials targeting CCR1 for RA, pso-
riasis, or multiple sclerosis have failed despite strong pre-clinical
data (Trebst et al., 2001; Proudfoot et al., 2010).
There are numerous hurdles in the development of such
inhibitors. Chemokine redundancy, with most receptors binding
numerous ligands and receptor heterodimerization ensures that
a single molecule will not achieve full inhibition of a given lig-
and. Additionally, the timing of chemokine inhibition during the
disease process may be crucial and the window of effective inhibi-
tion narrow. For instance, the CXCR1/CXCR2 inhibitor, reparixin,
has no effect on hepatic I/R injury when administered immedi-
ately after the injury, yet when administered 24 h after injury led
to a worse outcome (Clarke et al., 2011). Similarly, in murine
models of cardiac ischemia, AMD3100 can either increase or
decrease the extent of injury based on the dosing protocol (Dai
et al., 2010; Jujo et al., 2010). Finally, the choice of disease may
determine if an inhibitor is successful. Mozobil (AMD3100), a
CXCR4 inhibitor, is currently used for hematopoietic stem cell
mobilization, yet failed as an HIV-entry inhibitor. Despite these
difficulties successful chemokine inhibitors have been developed
including maraviroc (CCR5 HIV-entry inhibitor) which may also
show beneficial effects in patients with liver disease (Macias et al.,
2012).
CONCLUSION
Chemokines are a large family of molecules whose function has
expanded to now include immune cell infiltration, cellular sur-
vival and proliferation, vascular angiogenesis, organ fibrogene-
sis, and tumor metastasis. The interactions between chemokines,
cytokines, and growth factors add additional levels of complex-
ity to the networks and allow for spatial and temporal regulation.
While most studies have focused on their adverse role in acute
liver disease, a growing number of studies have revealed the bene-
ficial role that they may play during injury as well. The availability
of small molecule inhibitors for many chemokine axes makes
them promising targets for therapeutics. However, given the many
roles of chemokines during disease, a greater understanding of the
underlying mechanisms is mandated.
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